

PRODUCT
CANDIDATE:

CF-101 (piclidenoson)

c\$600M

Annual Canadian market for
plaque psoriasis treatments

c\$41M

Annual Canadian market for
moderate to severe plaque
psoriasis treatments

Sources:
Canadian Dermatology Association,
IQVIA CompuScript Dec 2023 MAT

cipherTM
PHARMACEUTICALS

Acquired marketing
rights from:

Can-Fite BioPharma (NYSE:CANF)

CANFITE
BioPharma Ltd

Indication:

Plaque psoriasis

Advantage:

Demonstrated increased efficacy with lower adverse events

Regulatory next step:

Phase III COMFORT study completed,
Pivotal Phase III study expected to start early 2024

Timeline

Pivotal trial results expected by 2026